Joint Corp
NASDAQ:JYNT

Watchlist Manager
Joint Corp Logo
Joint Corp
NASDAQ:JYNT
Watchlist
Price: 8.73 USD -1.02% Market Closed
Market Cap: $123.2m

Joint Corp
Investor Relations

The Joint Corp. engages in the development, ownership, operation, support, and management of chiropractic clinics. The company is headquartered in Scottsdale, Arizona and currently employs 316 full-time employees. The company went IPO on 2014-11-11. Its segments include Corporate Clinics and Franchise Operations. Corporate Clinics segment is comprised of the operating activities of the Company-owned or managed clinics. The firm operates or manages approximately 96 clinics under this segment. Franchise Operations segment is comprised of the operating activities of the franchise business unit. The franchise system consists of approximately 610 clinics in operation. The company offers a range of membership and wellness packages. The company offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention. Each patient's records are digitally updated for ready retrieval in its data storage system by its chiropractors in compliance with various applicable medical records security and privacy regulations.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q4 2025
Call Date
Mar 12, 2026
AI Summary
Q4 2025

Transformation progress: Management says Joint 2.0 is on track to complete by year-end and refranchising is nearly finished — 48 corporate clinics remain (down from 135) with active LOIs/APAs for 27 clinics.

Q4 results: System-wide sales were $140 million (down 3.9% YoY); consolidated revenue was $15.2 million (up ~3% YoY); consolidated adjusted EBITDA was $3.6 million (up 7.8% YoY).

Full-year picture: System-wide sales were $532 million (flat YoY); consolidated adjusted EBITDA rose to $13.0 million; consolidated net income was $2.9 million vs a loss in 2024.

Marketing & demand: Company shifted messaging to pain relief, moved spend from local to national, and invested in SEO/AI-search — early sequential improvements in leads and new patients but new patient flow remains the weakest link.

Pricing & ops: Piloting $2/$5/$10 price tests across ~300 clinics (early signs favor $10); conversion and retention initiatives include new Align 1/2 lower-frequency plans and in-clinic conversion training.

2026 guidance: System-wide sales $519M–$552M; comp sales -3% to +3%; consolidated adjusted EBITDA $12.5M–$13.5M. No pricing assumed in the guide.

Pure-play franchisor model: Management outlined mid-2026 run-rate targets: revenue ~11% of system-wide sales, adjusted EBITDA margin 19%–21%, free cash flow conversion 60%–70%.

Capital allocation: Repurchased 1.3M shares in 2025 for $11.3M; priorities post-refranchise are growth investments, buybacks (RD territories) and continued repurchases.

Key Financials
System-wide sales (Q4 2025)
$140 million
Comp sales (Q4 2025)
down 3.8%
Revenue (consolidated, Q4 2025)
$15.2 million
Cost of revenues (Q4 2025)
$2.8 million
Selling & marketing expense (Q4 2025)
$3.5 million
G&A expense (Q4 2025)
$7.7 million
Consolidated net income (Q4 2025)
$1.0 million
Consolidated adjusted EBITDA (Q4 2025)
$3.6 million
Adjusted EBITDA (continuing operations, Q4 2025)
$1.6 million
System-wide sales (full-year 2025)
$532 million
Revenue (full-year consolidated 2025)
$54.9 million
Consolidated net income (full-year 2025)
$2.9 million
Net loss (continuing operations, full-year 2025)
$268,000
Adjusted EBITDA (consolidated, full-year 2025)
$13.0 million
Adjusted EBITDA (continuing operations, full-year 2025)
$3.1 million
Unrestricted cash and cash equivalents (Dec 31, 2025)
$23.6 million
Share repurchases (Q4 2025)
1.1 million shares for $9.0 million (avg $8.45 per share)
Share repurchases (full-year 2025)
1.3 million shares for $11.3 million (avg $8.73 per share)
Credit facility
$20.0 million (undrawn)
2026 guidance — System-wide sales
$519 million to $552 million
2026 guidance — Comp sales
negative 3% to positive 3%
2026 guidance — Consolidated adjusted EBITDA
$12.5 million to $13.5 million
Pure-play franchisor: revenue as % of system-wide sales (target)
~11%
Run-rate gross margin (post-refranchise)
83% to 85% of revenues
Run-rate G&A (post-refranchise)
40% to 42% of revenues
CapEx (run-rate)
~3% of revenues
Free cash flow conversion (run-rate)
60% to 70% (free cash flow / adjusted EBITDA)
Run-rate adjusted EBITDA margin (post-refranchise)
19% to 21%
Run-rate net income margin (post-refranchise)
13% to 15%
Sensitivity — adjusted EBITDA margin at 5% revenue growth
20% to 22%
Sensitivity — net income margin at 5% revenue growth
14% to 16%
Sensitivity — adjusted EBITDA margin at 10% revenue growth
22% to 24%
Sensitivity — net income margin at 10% revenue growth
16% to 18%
Internal IRR target for growth projects
25%
Clinic count (year-end 2025)
960 total clinics (885 franchised, 75 company-owned)
Earnings Call Recording
Other Earnings Calls

Management

Mr. Jake Singleton CPA
Chief Financial Officer
No Bio Available
Mr. Sanjiv Razdan
CEO, President & Director
No Bio Available
Mr. Jorge Armenteros
Senior Vice President of Operations
No Bio Available
Mr. Charles Nelles
Chief Technology Officer
No Bio Available
Dr. Steven Knauf
Vice President of Chiropractic & Compliance
No Bio Available
Ms. Lori I. Abou Habib
Chief Marketing Officer
No Bio Available
Ms. Beth Gross
Senior Vice President of Human Resources
No Bio Available
Mr. Eric Simon
Senior Vice President of Franchise Sales & Development
No Bio Available
Mr. Craig P. Colmar J.D.
Secretary
No Bio Available

Contacts

Address
ARIZONA
Scottsdale
16767 N Perimeter Drive, Suite 110
Contacts
+14802455960.0
www.thejoint.com
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett